Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study

Cancer Gene Therapy volume 21, pages 91–94 (2014)Cite this article

Subjects

Abstract

A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic mechanism that can be measured by soluble forms of cytokeratin 18 (CK18) using M30 and M65 ELISAs, assays for caspase-cleaved (apoptotic) and uncleaved (necrotic) cell death, respectively. Therefore, we determined whether M30 and M65 levels in the urine after treatment could document all three mechanisms of cancer cell kill and also predict having a CR. High levels of both M30 and M65 were found in all patients within 24 h after treatment with all three types of cancer cell death occurring. Moreover, the return of both M30 and M65 levels in the urine to normal levels within 5 days or more after treatment was strongly associated with obtaining a CR (P=0.003). This is the first time that such assays have been used to study response to therapy in the urine of patients with bladder cancer and in the future may prove valuable in predicting clinical outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A et al. Phase I trial of intravesical recombinant adenovirus-mediated interferon-α2b formulated in syn3 for BCG failures in non-muscle-invasive bladder cancer. J Urol 2013; 190: 850–856.

    Article  CAS  Google Scholar 

  2. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L et al. Intravesical Ad-IFN alpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004; 10: 525–532.

    Article  CAS  Google Scholar 

  3. Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained:implications for clinical investigation. Cancer Gene Therapy 2006; 13: 125–130.

    Article  CAS  Google Scholar 

  4. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict WF, Dinney CP et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004; 64: 8973–8979.

    Article  CAS  Google Scholar 

  5. Zhang X-Q, Yang Z, Dong L, Papageorgiou A, McConkey D, Benedict WF . Adenoviral- mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Therapy 2007; 14: 241–250.

    Article  CAS  Google Scholar 

  6. Zhang X-Q, Dong L, Chapman E, Benedict WF . Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Therapy 2008; 12: 817–822.

    Article  Google Scholar 

  7. Zhang X-Q, Yang Z, Benedict WF . Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related related cytotoxicity. Cancer Gene Therapy 2011; 18: 260–264.

    Article  CAS  Google Scholar 

  8. Zhibo Y, Zhang XQ, Dinney CNP, Benedict WF . Direct cytotoxicity produced by adenoviral-mediated interferon α infection in interferon resistant cancer cells involves ER stress and caspase 4 activation. Cancer Gene Therapy 2011; 18: 609–616.

    Article  Google Scholar 

  9. Fisher MB, Zhang X-Q, McConkey DJ, Benedict WF . Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker. Cancer Gene Therapy 2009; 16: 567–572.

    Article  CAS  Google Scholar 

  10. Linder S . Cytokeratin markers come of age. Tumor Biol 2007; 28: 189–195.

    Article  CAS  Google Scholar 

  11. de Hass EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJH, Lancashire LJ et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug –sensitive tumor, testicular cancer. Neoplasia 2008; 10: 1041–1048.

    Article  Google Scholar 

Download references

Acknowledgements

This study is supported by a GU SPORE in Bladder Cancer (P50 CA91846).

Author information

Authors and Affiliations

  1. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    W F Benedict, X-Q Zhang & Z Yang

  2. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M Fisher & C N P Dinney

  3. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M F Munsell

Authors
  1. W F Benedict
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X-Q Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M F Munsell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C N P Dinney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W F Benedict.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benedict, W., Fisher, M., Zhang, XQ. et al. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study. Cancer Gene Ther 21, 91–94 (2014). https://doi.org/10.1038/cgt.2014.1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2014.1

Keywords

This article is cited by

Search

Advanced search

Quick links